Skip to main content
. Author manuscript; available in PMC: 2013 Sep 30.
Published in final edited form as: Inflamm Res. 2012 Jul 10;61(9):915–926. doi: 10.1007/s00011-012-0513-z

Table 1.

Specific α7nAChR pharmaceutical agonists investigated in the literature for their in vivo therapeutic effects on the pathogenesis of a number of inflammatory conditions

α7nAChR specific
agonist
Animal
model
Inflammatory
condition
Outcome Reference
GTS-21 Mouse Endotoxemia/
 sepsis
Improved survival coinciding with decreased serum levels of TNF-α and HMGB1 [66]
Mouse Pancreatitis Lower pancreatic inflammation with decreased plasma levels of IL-6 and amylase [67]
PNU-282987 Mouse Acute lung injury Decreased excess lung water and lung vascular permeability with reduced TNF-α and MIP2 in BAL [68]
AR-R17779 Mouse Rheumatoid
 arthritis
Ameliorated clinical arthritis and reduced synovial inflammation with a reduction of TNF-α levels [33]
Mouse Intestinal
 inflammation
Prevents postoperative ileus characterised by reduced inflammatory cell recruitment [69]
DMPP Mouse Asthma Reduced airway inflammation with reduced IgE and number of eosinophils in BAL [70]
TC-7020 Mouse Type 2 diabetes Reduced weight gain, glucose and glycated hemoglobin levels and lowered plasma levels of TNF-α [71]